Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Aranesp (Darbepoetin Alfa) to Treat Anemia in Prostate Cancer Patients.

NCT00245895 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT00245895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00245895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Aranesp (Darbepoetin Alfa) to Treat Anemia in Prostate Cancer Patients.
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2003
Completion date
February 28, 2005
Enrollment
20 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, prostate cancer